ATE456797T1 - Verwendung von nogo-c bei der beurteilung von herzversagen - Google Patents

Verwendung von nogo-c bei der beurteilung von herzversagen

Info

Publication number
ATE456797T1
ATE456797T1 AT07004532T AT07004532T ATE456797T1 AT E456797 T1 ATE456797 T1 AT E456797T1 AT 07004532 T AT07004532 T AT 07004532T AT 07004532 T AT07004532 T AT 07004532T AT E456797 T1 ATE456797 T1 AT E456797T1
Authority
AT
Austria
Prior art keywords
nogo
heart failure
marker
concentration
assessing heart
Prior art date
Application number
AT07004532T
Other languages
English (en)
Inventor
Dirk Block
Georg Hess
Hendrik Huedig
Der Eltz Herbert Von
Ursula-Henrike Wienhues-Thelen
Andrew Emili
Vincent Fong
Anthony Gramolini
Ruth Isserlin
Thomas Kislinger
Peter Liu
David Maclennan
Original Assignee
Hoffmann La Roche
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Toronto filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE456797T1 publication Critical patent/ATE456797T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Electrotherapy Devices (AREA)
  • Compositions Of Oxide Ceramics (AREA)
AT07004532T 2007-03-06 2007-03-06 Verwendung von nogo-c bei der beurteilung von herzversagen ATE456797T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07004532A EP1967853B1 (de) 2007-03-06 2007-03-06 Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Publications (1)

Publication Number Publication Date
ATE456797T1 true ATE456797T1 (de) 2010-02-15

Family

ID=38124144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07004532T ATE456797T1 (de) 2007-03-06 2007-03-06 Verwendung von nogo-c bei der beurteilung von herzversagen

Country Status (4)

Country Link
EP (1) EP1967853B1 (de)
AT (1) ATE456797T1 (de)
DE (1) DE602007004570D1 (de)
ES (1) ES2339284T3 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
CN102422157B (zh) * 2009-04-27 2014-10-29 霍夫曼-拉罗奇有限公司 内皮抑制素作为心力衰竭标记的应用
CN105548563B (zh) * 2009-07-27 2017-09-22 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途
CN113449757A (zh) * 2020-03-26 2021-09-28 太原理工大学 心衰诊断模型的构建方法、构建系统和心衰诊断装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure

Also Published As

Publication number Publication date
EP1967853A1 (de) 2008-09-10
DE602007004570D1 (de) 2010-03-18
EP1967853B1 (de) 2010-01-27
ES2339284T3 (es) 2010-05-18

Similar Documents

Publication Publication Date Title
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2011012268A8 (en) Use of mimecan in the assessment of heart failure
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
BRPI0618391A2 (pt) método para identificar um nucleotìdeo individual, método para seqüenciar uma seqüência de ácido nucleico alvo, e, kit para seqüenciar um ácido nucleico
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
DE602006014379D1 (de) Neurodegenerative marker für depression.
ATE554389T1 (de) Apex als marker für lungenkrebs
DE602005023529D1 (de) Homogener nachweis von analyten
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2007134235A3 (en) Hla alleles associated with adverse drug reactions and methods for detecting such
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
ATE424560T1 (de) Marker für neuromyelitis optica
ATE415662T1 (de) Bestimmung der tatsächlichen zeit, die ein prozessor bei der ausführung eines codeteiles aufwendet
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
ATE456797T1 (de) Verwendung von nogo-c bei der beurteilung von herzversagen
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
ATE454632T1 (de) Verfahren zur beurteilung der lebensfähigkeit von embryos
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
ATE473290T1 (de) Proteomweite quantifizierung kleiner an zelluläre zielproteine gebundener moleküle
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602006013109D1 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties